Clinical trial
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With…
NCT00316875 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00316875 |
|---|---|
| Title | Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | lapatinib ditosylate, Doxil |
| Enrollment | 23 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Apr 21, 2006 |
| Last update posted | Nov 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: